Given the reports that SUMO2 and SUMO2 conjugated proteins are identified in exosomes [72], SUMO2 and its target proteins can serve as a circulating biomarkers for determining cancer risk and for evaluating the chemotherapy response. This evidence concerns the gene SUMO2 and cancer.